Skip to main content
. 2023 Jun 30;9(7):533. doi: 10.3390/gels9070533

Figure 1.

Figure 1

Schematic representation of ERT@HMSNs/gel composite to treat NSCLC. Hollow mesoporous silica nanoparticles (HMSNs) act as a carrier for encapsulating erlotinib, aiming to enhance its therapeutic efficacy and mitigate drug-related toxicity. To endure homogeneity and stability of the injectable matrix, PLEL added to the ERT@HMSNs solution. The evaluation included assessing transition from sol to gel phase and the sustained release of the drug. Adopted with permission [77].